BRAF and melanoma: Dabrafenib mesilate was approved in August 2013 for the treatment of patients with BRAF V600 mutation–positive unresectable stage III or stage IV melanoma (190), with approval of its use in combination with the reversible allosteric inhibitor of MEK (MEK1 and MEK2) trametinib shortly following in 2014 (191).